查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573895

多发性骨髓瘤治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Multiple Myeloma Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 198 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球多发性骨髓瘤治疗市场规模为 254 亿美元，在多发性骨髓瘤发病率不断上升以及治疗方案大幅进步的推动下，2024 年至 2032 年将以 6.4% 的复合年增长率增长。意识的提高和诊断技术的改进导致了更早的发现和更高的病例报告。此外，标靶治疗和免疫疗法等创新疗法的发展改变了患者的治疗结果，提供了更有效和个人化的选择。随着医疗保健提供者采用这些进步以及越来越多的患者寻求治疗，对多发性骨髓瘤治疗的需求将继续大幅增长。

多发性骨髓瘤治疗行业根据治疗类型、给药途径、疾病类型、最终用途和地区进行划分。

2023 年，标靶治疗领域的销售额达到 87 亿美元，因为它能够精确攻击癌细胞，同时不伤害健康组织。这些疗法包括单株抗体和蛋白酶体抑制剂，已证明在改善患者预后和延长存活率方面具有显着疗效。随着正在进行的研究不断揭示新的标靶和组合，标靶治疗的吸引力必将增加。它们在临床环境中的日益普及进一步巩固了该细分市场在市场中的主导地位。

到 2032 年，医院部分将扩大到 243 亿美元，主要是因为它们作为癌症患者的初级治疗中心。医院提供全面的护理，包括先进的诊断工具、专门的治疗方案以及多学科医疗保健专业人员团队的帮助。随着多发性骨髓瘤治疗的复杂性增加，医院设备精良，可以有效地管理和实施这些治疗。此外，在医院寻求治疗的癌症患者数量不断增加，进一步推动了这一领域的治疗需求。

在先进的医疗基础设施和高癌症诊断率的推动下，北美多发性骨髓瘤治疗市场的复合年增长率将达到 6.2%，到 2032 年将达到 204 亿美元。该地区受益于研发方面的大量投资，从而引入了创新疗法。此外，人口老化的加剧和对多发性骨髓瘤认识的提高导致了更高的治疗需求。进入专业医疗中心和全面的健康保险范围进一步增加了患者获得治疗的机会，使北美成为全球市场的显着贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 多发性骨髓瘤盛行率增加
      • 改进的诊断技术
      • 患者意识和教育
    • 产业陷阱与挑战
      • 治疗费用高
      • 与治疗相关的不良反应
  • 成长潜力分析
  • 监管环境
  • 管道分析
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

  • 主要趋势
  • 化疗
  • 标靶治疗
  • 免疫调节剂
  • 干细胞移植
  • 放射治疗
  • 其他治疗类型

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

  • 主要趋势
  • 口服
  • 注射用

第 7 章：市场估计与预测：按疾病类型，2021 - 2032

  • 主要趋势
  • 活动性多发性骨髓瘤
  • 冒烟型多发性骨髓瘤

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 专科诊所
  • 家庭护理设置
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Service Provider
  • Medication Manufacturers
简介目录
Product Code: 11123

The Global Multiple Myeloma Therapeutics Market held USD 25.4 billion in 2023 and will grow at 6.4% CAGR from 2024 to 2032, propelled by the increasing incidence of multiple myeloma, coupled with substantial advancements in treatment options. Rising awareness and improved diagnostic techniques have led to earlier detection and higher reported cases. Also, the development of innovative therapies, such as targeted treatments and immunotherapies, has transformed patient outcomes, providing more effective and personalized options. As healthcare providers adopt these advancements and more patients seek treatment, the demand for multiple myeloma therapeutics will continue to expand considerably.

The multiple myeloma therapeutics industry is divided based on treatment type, route of administration, disease type, end-use, and region.

The targeted therapy segment witnessed USD 8.7 billion in 2023, owing to its ability to precisely attack cancer cells while sparing healthy tissues. These therapies, which include monoclonal antibodies and proteasome inhibitors, have demonstrated significant efficacy in improving patient outcomes and prolonging survival rates. As ongoing research continues to unveil new targets and combinations, the appeal of targeted therapies is set to increase. Their rising adoption in clinical settings further solidifies this segment's dominant position in the market.

The hospitals segment will expand to USD 24.3 billion by 2032, primarily due to their role as primary treatment centers for cancer patients. Hospitals provide comprehensive care, including advanced diagnostic tools, specialized treatment regimens, and access to multidisciplinary teams of healthcare professionals. As the complexity of multiple myeloma therapies increases, hospitals are well-equipped to manage and administer these treatments effectively. Besides, the rising number of cancer patients seeking treatment in hospital settings further drives the demand for therapeutics in this segment.

North America multiple myeloma therapeutics market will demonstrate a 6.2% CAGR and register USD 20.4 billion by 2032, driven by advanced healthcare infrastructure and high rates of cancer diagnosis. The region benefits from sizable investments in research and development, leading to the introduction of innovative therapies. Furthermore, a growing aging population and increased awareness about multiple myeloma contribute to higher treatment demand. Access to specialized medical centers and comprehensive health insurance coverage further enhance patient access to therapies, making North America a notable contributor to the global market.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of multiple myeloma
      • 3.2.1.2 Improved diagnostic technologies
      • 3.2.1.3 Patient awareness and education
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High treatment costs
      • 3.2.2.2 Adverse effects associated with treatment
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Chemotherapy
  • 5.3 Targeted therapy
  • 5.4 Immunomodulating agents
  • 5.5 Stem cell transplantation
  • 5.6 Radiation therapy
  • 5.7 Other treatment types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oral
  • 6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Active multiple myeloma
  • 7.3 Smoldering multiple myeloma

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Specialty clinics
  • 8.4 Homecare settings
  • 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Service Provider
    • 10.1.1 Cleveland Clinic
    • 10.1.2 Dana-Farber Cancer Institute, Inc.
    • 10.1.3 Mayo Foundation for Medical Education and Research (MFMER)
    • 10.1.4 MD Anderson Cancer Center
    • 10.1.5 Memorial Sloan Kettering Cancer Center
  • 10.2 Medication Manufacturers
    • 10.2.1 AbbVie Inc.
    • 10.2.2 Amgen Inc.
    • 10.2.3 Bristol-Myers Squibb Company.
    • 10.2.4 Glenmark Pharmaceuticals Ltd.
    • 10.2.5 Johnson and Johnson Services, Inc
    • 10.2.6 Merck and Co, Inc.
    • 10.2.7 Novartis AG
    • 10.2.8 Sanofi S.A.
    • 10.2.9 Takeda Pharmaceutical Company Limited